Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03014687 · ClinicalTrials.gov registry record · Phase 4

Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

A Phase 4 study of Pituitary Adenoma and Antibiotics, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.

Recruiting
Registry status
Phase 4
Development phase
116
Enrollment target
1
Study location

NCT03014687 is a Phase 4 study of Pituitary Adenoma and Antibiotics that is actively recruiting participants, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 116 participants, below the 276-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03014687, a Phase 4 study of Pituitary Adenoma and Antibiotics, is actively recruiting participants, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.

RECRUITING
Registry status
Phase 4
Development phase
116 participants
Enrollment target
1
Study location

Study Summary

To find out whether oral antibiotics given after transsphenoidal endoscopic surgery for pituitary adenoma improves sinus and nasal symptoms, reduces the incidence of infection (sinusitis), and helps mucosal healing in the nasal passages.

Interventions

  • DRUG Placebo
  • DRUG Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole

Study Locations (1)

Arizona

  • Barrow Brain and Spine - Phoenix

Trial Details

FieldValue
Enrollment Target 116 participants
Start Date 2017-07-01
Est. Completion 2019-07
Phase Phase 4

What the Registry Record Tells You About NCT03014687

The ClinicalTrials.gov registry entry for NCT03014687 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 276-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (58% lower). The listed sponsor is St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pituitary Adenoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03014687 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT03014687 about?

NCT03014687 is a clinical study titled "Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions". To find out whether oral antibiotics given after transsphenoidal endoscopic surgery for pituitary adenoma improves sinus and nasal symptoms, reduces the incidence of infection (sinusitis), and helps mucosal healing in the nasal passages.

What is the current status of trial NCT03014687?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 116 participants. The study started on 2017-07-01. Estimated completion is 2019-07.

What conditions does trial NCT03014687 study?

This clinical trial studies the following conditions: Pituitary Adenoma, Antibiotics.

What interventions are being tested in trial NCT03014687?

The interventions under investigation include: Placebo (DRUG), Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole (DRUG).

Who is sponsoring clinical trial NCT03014687?

This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03014687 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pituitary Adenoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.